Understanding BZO Results on Drug Tests

What BZO Means on a Drug Test

BZO stands for benzodiazepines, a class of prescription medications commonly used to treat anxiety, insomnia, and seizure disorders. When BZO appears on a drug test result, it indicates that benzodiazepine compounds were detected in the person's system at the time of testing. Understanding what this result means requires knowing both what benzodiazepines are and how they show up in standard drug screening tests.

Benzodiazepines are central nervous system depressants that have been prescribed in the United States since the 1960s. According to the National Institute on Drug Abuse, approximately 30 million benzodiazepine prescriptions are filled annually in the United States. Common prescription benzodiazepines include diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan), and clonazepam (Klonopin). These medications work by enhancing the effect of neurotransmitters in the brain, producing a calming effect on the nervous system.

A positive BZO result on a drug test does not automatically indicate misuse or illegal activity. The test simply shows the presence of benzodiazepine metabolites in urine, blood, or saliva. A person may test positive for legitimate reasons, such as taking a prescribed medication as directed by a physician. However, a positive result can also indicate use of benzodiazepines obtained without a prescription, use in combination with other substances, or use in ways other than prescribed.

Most standard drug screening tests use immunoassay technology to detect benzodiazepines. This type of test has a detection window of approximately 3 to 7 days for most benzodiazepines in urine, though some longer-acting benzodiazepines like diazepam may be detectable for up to 30 days. The specific detection time depends on the individual's metabolism, kidney function, body mass index, and the particular benzodiazepine involved.

Practical Takeaway: A BZO-positive result indicates benzodiazepines were in the system during testing. This result alone does not prove misuse—it may reflect prescribed use, non-prescribed use, or other circumstances. Understanding the context of the test and the person's medication history is necessary to interpret the result accurately.

Common Benzodiazepines That Trigger BZO Positive Results

Multiple benzodiazepines can produce a positive BZO result because standard immunoassay tests detect the drug class rather than individual medications. Different benzodiazepines have different chemical structures, potencies, and durations of action, but most will register as BZO on a screening test. Knowing which medications fall into this category can help explain why a test result came back positive.

Short-acting benzodiazepines like alprazolam (Xanax) and lorazepam (Ativan) are among the most frequently prescribed. Alprazolam is prescribed for generalized anxiety disorder and panic disorder, with approximately 48 million prescriptions filled in the United States in 2022. Lorazepam is commonly used in hospital and emergency settings for acute anxiety and also prescribed for longer-term use. Both medications typically produce effects within 30 minutes to an hour and have detection windows of 3 to 5 days in urine screening.

Intermediate-acting benzodiazepines include estazolam and temazepam, which are primarily prescribed for insomnia. Temazepam is one of the most commonly prescribed benzodiazepines for sleep disorders. These medications typically remain detectable in urine for 5 to 7 days. Long-acting benzodiazepines such as diazepam (Valium) and clonazepam (Klonopin) have much longer detection windows. Diazepam, which has been used clinically since 1963, can remain detectable in urine for 30 days or longer because it is metabolized slowly and produces active metabolites that persist in the body.

Some benzodiazepines are used less commonly in medical settings but may still be encountered. Flurazepam, used for insomnia; chlordiazepoxide, used for alcohol withdrawal; and oxazepam, used for anxiety, will all produce positive BZO results. Additionally, some benzodiazepines are obtained illegally and commonly abused, including flunitrazepam (Rohypnol), which is not approved for medical use in the United States but is manufactured for use in other countries.

Practical Takeaway: More than a dozen benzodiazepines exist, ranging from short-acting to long-acting formulations. Any of these medications, whether prescribed or obtained otherwise, will produce a positive BZO result on a standard drug screening test. The specific medication cannot be determined from a standard BZO result—that would require more detailed laboratory analysis.

How Drug Tests Detect Benzodiazepines

Understanding how benzodiazepines are detected involves learning about the different types of drug tests available and the technology used in each. Most workplace, legal, and medical drug screening programs use immunoassay tests as an initial screening method. These tests are relatively inexpensive, fast, and can be performed on-site or in a laboratory. When an immunoassay detects benzodiazepines, the result is reported as BZO or BZ on the test report.

Immunoassay tests work by using antibodies that bind to benzodiazepine molecules or their metabolites in a test sample. The test contains a threshold concentration, called a cutoff level. If benzodiazepine metabolites in the sample exceed this cutoff, the test returns a positive result. The standard cutoff level for benzodiazepines in urine drug screening is 300 nanograms per milliliter (ng/mL), according to guidelines set by the Substance Abuse and Mental Health Services Administration (SAMHSA). Some laboratories may use different cutoff levels, such as 200 ng/mL, which would be more sensitive and more likely to detect lower concentrations.

Benzodiazepines can be detected in multiple types of samples. Urine testing is the most common method used in workplace and legal settings because it is non-invasive and has a relatively long detection window. Blood testing detects more recent use, typically within the past 24 to 48 hours, and is often used in DUI investigations or emergency medical settings. Saliva testing is increasingly used because it is non-invasive and can detect use within the past 24 hours. Hair testing can detect benzodiazepine use over a much longer period, potentially 90 days or more, though hair testing for benzodiazepines is less commonly used than for other drugs.

When an initial immunoassay test returns positive for BZO, many testing programs perform a confirmatory test using a more sophisticated method such as gas chromatography-mass spectrometry (GC-MS). This confirmation test can identify which specific benzodiazepine is present and provide a quantitative measurement of the concentration. This information becomes important when distinguishing between prescribed use and other use, or when determining whether a medication was taken at therapeutic doses.

Practical Takeaway: Standard drug tests use immunoassay technology to detect benzodiazepines as a class, not as individual medications. Confirmatory tests using GC-MS can identify the specific benzodiazepine present. Understanding these testing methods helps explain why a BZO result appears and what additional testing might clarify the situation.

Detection Windows and Factors Affecting Test Results

How long benzodiazepines remain detectable in the body varies significantly depending on the specific drug, the individual's body characteristics, and other factors. For urine drug testing, the most commonly used method, detection windows can range from three days to one month or longer. A person who took a single dose of a short-acting benzodiazepine like alprazolam might test positive for approximately three to five days, while someone taking a long-acting benzodiazepine like diazepam might test positive for much longer, even if they stop taking the medication.

Individual variation in detection windows occurs because benzodiazepines are metabolized at different rates depending on the person's age, liver function, kidney function,